What the FDA labels say about taking them together
Benazepril and everolimus
Benazepril's FDA label of September 30, 2025 names everolimus in its drug interactions section; everolimus's label does not name benazepril itself but warns about its class (ACE inhibitors). The benazepril label: “Patients receiving coadministration of ACE inhibitor and mTOR inhibitor therapy or a neprilysin inhibitor may be at increased risk for angioedema.”
Check it at the source: the benazepril FDA label on DailyMed (effective September 30, 2025, Validus Pharmaceuticals LLC); the everolimus FDA label on DailyMed (effective June 1, 2026, Novartis Pharmaceuticals Corporation).
What does the benazepril label say about everolimus?
Benazepril label, drug interactionsTarget of Rapamycin (mTOR) Inhibitors Patients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema.
Benazepril label, warnings and precautionsPatients receiving coadministration of ACE inhibitor and mTOR (mammalian target of rapamycin) inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy or a neprilysin inhibitor may be at increased risk for angioedema [see Drug Interactions (7.7) ].
Source: FDA drug label (Lotensin), Validus Pharmaceuticals LLC, effective September 30, 2025 (SPL set 2abb091b-a53e-46b0-9b84-e5ee8f2bdd8e), via openFDA; the full label on DailyMed
What does the everolimus label say about benazepril?
Everolimus's label does not name benazepril itself; it warns about its class (ACE inhibitors):
Everolimus label, drug interactionsUse of Angiotensin Converting Enzyme (ACE) Inhibitors Patients taking concomitant ACE inhibitors with AFINITOR/AFINITOR DISPERZ may be at increased risk for angioedema.
Everolimus label, drug interactionsAvoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)].
Source: FDA drug label (Afinitor), Novartis Pharmaceuticals Corporation, effective June 1, 2026 (SPL set 2150f73a-179b-4afc-b8ce-67c85cc72f04), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Benazepril | Everolimus | |
|---|---|---|
| Labeled for | High blood pressure | Breast cancer, Seizures and epilepsy, Organ transplant rejection |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.0789 per tablet 20 mg tablet | $26.32 per tablet 10 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once